 |
|
 |
FDA Home Page | Search
FDA Site | FDA A-Z Index | Contact
FDA
Human Immunodeficiency Virus and
Acquired Immunodeficiency Syndrome
Revised: January 31, 2003
This e-mail list, established by the Division of Antiviral Drug Products (Center for Drug Evaluation and Research) and the Office of Special Health Issues (Office of the Commissioner) of the Food and Drug Administration, provides updates on safety and regulatory issues related to HIV/AIDS products as they become available (rather than on a regularly scheduled basis).
The e-mail list gives patients, industry, academia, other government agencies, and other interested parties one source for FDA HIV/AIDS related information on a variety of topics, including:
The e-mail list is not intended or designed to accept comments or input.
Join or leave the e-mail list: Your name and e-mail address are considered confidential.
Once you subscribe, you will receive a confirmation e-mail giving you instructionsfor
completing the subscription process.
Contact the Office of Special Health Issues if you have problems or questions about subscribing to this e-mail list.
Register for FDA's Center for Biologics Evaluation and Research e-mail list if you are interested in regulatory guidance and requirements for blood safety.